Faruqi & Faruqi Settles Lidoderm Antitrust Litigation For $166 Million
Faruqi & Faruqi’s Peter Kohn was at the helm for direct purchasers during the lengthy and complex “pay for delay” antitrust case known as the Lidoderm Antitrust Litigation, pending in the United States District Court for the Northern District of California. The case resulted in a proposed settlement amounting to $166 million for the direct purchaser class, and generated several scholarly decisions by the Honorable William H. Orrick, III, including on the issue of attorney-client privilege waivers, class certification, and summary judgment in a “pay for delay” case. The settlement is yet another success for the Faruqi firm, who are on the forefront of pharmaceutical antitrust enforcement, and who were years ahead of the United States Federal Trade Commission in investigating, bringing suit, and obtaining monetary relief over the Lidoderm “pay for delay” deal.
About Faruqi & Faruqi, LLP
Faruqi & Faruqi, LLP focuses on complex civil litigation, including securities, antitrust, wage and hour, and consumer class actions as well as shareholder derivative and merger and transactional litigation. The firm is headquartered in New York, and maintains offices in California, Delaware, Georgia, and Pennsylvania.
Since its founding in 1995, Faruqi & Faruqi, LLP has served as lead or co-lead counsel in numerous high-profile cases which ultimately provided significant recoveries to investors, direct purchasers, consumers and employees.
To contact the author of this blog or the offices of Faruqi & Faruqi, please call us at (877) 476-7797.
About Peter Kohn
Peter Kohn is Chair of Pharmaceutical Litigation and Co-Chair of Antitrust at Faruqi & Faruqi, LLP with almost 20 years of antitrust experience.